-
1
-
-
1442299103
-
Worldwide prevalence of hypertension. A systematic review
-
KEARNEY PM, WHELTON M, REYNOLDS K, WHELTON PK, HE J: Worldwide prevalence of hypertension. A systematic review. J. Hypertens. (2004) 22:11-18.
-
(2004)
J. Hypertens.
, vol.22
, pp. 11-18
-
-
Kearney, P.M.1
Whelton, M.2
Reynolds, K.3
Whelton, P.K.4
He, J.5
-
2
-
-
0037181148
-
Residual lifetime risk for developing hypertension in middle-aged women and men: The Framingham Heart Study
-
VASAN RS, BEISER A, SESHADRI S et al.: Residual lifetime risk for developing hypertension in middle-aged women and men: The Framingham Heart Study. JAMA (2002) 287:1003-1010.
-
(2002)
JAMA
, vol.287
, pp. 1003-1010
-
-
Vasan, R.S.1
Beiser, A.2
Seshadri, S.3
-
3
-
-
0038460302
-
The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure the JNC 7 report
-
CHOBANIAN AV, BAKRIS GL, BLACK HR et al.: The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure the JNC 7 report. JAMA (2003) 289:2560-2572.
-
(2003)
JAMA
, vol.289
, pp. 2560-2572
-
-
Chobanian, A.V.1
Bakris, G.L.2
Black, H.R.3
-
4
-
-
0027461577
-
Single-drug therapy for hypertension in men - A comparison of six antihypertensive agents with placebo
-
MATERSON BJ, REDA DJ, CUSHMAN WC et al.: Single-drug therapy for hypertension in men - a comparison of six antihypertensive agents with placebo. N. Engl. J. Med. (1993) 328:914-921.
-
(1993)
N. Engl. J. Med.
, vol.328
, pp. 914-921
-
-
Materson, B.J.1
Reda, D.J.2
Cushman, W.C.3
-
5
-
-
0028930346
-
Department of Veterans Affairs singic-drug therapy of hypertension study. Revised figures and new data. Department of Veterans Affairs Cooperative Study Group - Antihypertensive Agents
-
MATERSON BJ, REDA DJ, CUSHMAN WC: Department of Veterans Affairs singic-drug therapy of hypertension study. Revised figures and new data. Department of Veterans Affairs Cooperative Study Group - Antihypertensive Agents. Am. J. Hypertens. (1995) 8:189-192.
-
(1995)
Am. J. Hypertens.
, vol.8
, pp. 189-192
-
-
Mateson, B.J.1
Reda, D.J.2
Cushman, W.C.3
-
6
-
-
0035148501
-
Baseline characteristics and elderly blood pressure control in the CONVINCE trial
-
BLACK HR, ELLIOTT WJ, NEATON JD et al.: Baseline characteristics and elderly blood pressure control in the CONVINCE trial. Hypertension (2001) 37:12-18.
-
(2001)
Hypertension
, vol.37
, pp. 12-18
-
-
Black, H.R.1
Elliott, W.J.2
Neaton, J.D.3
-
7
-
-
0036863587
-
Success and predictors of blood pressure control in diverse north american settings: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)
-
CUSHMAN WC, FORD CE, CUTLER JA et al.: Success and predictors of blood pressure control in diverse north american settings: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). J. Clin. Hypertens. (2002) 4:393-404.
-
(2002)
J. Clin. Hypertens.
, vol.4
, pp. 393-404
-
-
Cushman, W.C.1
Ford, C.E.2
Cutler, J.A.3
-
9
-
-
0031746034
-
Important drug-drug interactions in the elderly
-
SEYMOUR RM, ROUTLEDGE PA: Important drug-drug interactions in the elderly. Drugs Aging (1998) 12:485-494.
-
(1998)
Drugs Aging
, vol.12
, pp. 485-494
-
-
Seymour, R.M.1
Routledge, P.A.2
-
11
-
-
0028453113
-
Polypharmacy in the aged. Practical solutions
-
STEWART RB, COOPER JW: Polypharmacy in the aged. Practical solutions. Drugs Aging (1994) 4:449-461.
-
(1994)
Drugs Aging
, vol.4
, pp. 449-461
-
-
Stewart, R.B.1
Cooper, J.W.2
-
12
-
-
0043124614
-
Drug interactions with ARBs: A comparison with other antihypertensives
-
UNGER T, KASCHINA E: Drug interactions with ARBs: a comparison with other antihypertensives. Drug Saf. (2003) 26 707-720.
-
(2003)
Drug Saf.
, vol.26
, pp. 707-720
-
-
Unger, T.1
Kaschina, E.2
-
13
-
-
0026890830
-
Adverse reactions as a cause of hospital admission in the aged
-
BEARD K: Adverse reactions as a cause of hospital admission in the aged. Drugs Aging (1992) 2:356-367.
-
(1992)
Drugs Aging
, vol.2
, pp. 356-367
-
-
Beard, K.1
-
14
-
-
0031012726
-
The costs of adverse drug events in hospitalized patients. Adverse Drug Events Prevention Study Group
-
BATES DW, SPELL N, CULLEN DJ et al.: The costs of adverse drug events in hospitalized patients. Adverse Drug Events Prevention Study Group. JAMA (1997) 277:307-311.
-
(1997)
JAMA
, vol.277
, pp. 307-311
-
-
Bates, D.W.1
Spell, N.2
Cullen, D.J.3
-
15
-
-
0032522873
-
Incidence of adverse drug reactions in hospitalized patients: A meta-analysis of prospective studies
-
LAZAROU J, POMERANZ BH, COREY PN: Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA (1998) 279:1200-1205.
-
(1998)
JAMA
, vol.279
, pp. 1200-1205
-
-
Lazarou, J.1
Pomeanz, B.H.2
Corey, P.N.3
-
16
-
-
0037169960
-
Implications of cytochrome P450 interactions when prescribing medication for hypertension
-
FLOCKHART DA, TANUS-SANTOS JE: Implications of cytochrome P450 interactions when prescribing medication for hypertension. Arch. Intern. Med. (2002) 162: 405-412.
-
(2002)
Arch. Intern. Med.
, vol.162
, pp. 405-412
-
-
Flockhart, D.A.1
Tanus-Santos, J.E.2
-
17
-
-
0034631883
-
Angiotensin II receptor blockers: Equal or preferred substitutes for ACE inhibitors?
-
GROSSMAN E, MESSERLI FH, NEUTEL JM: Angiotensin II receptor blockers: equal or preferred substitutes for ACE inhibitors? Arch. Intern. Med. (2000) 160:1905-1911.
-
(2000)
Arch. Intern. Med.
, vol.160
, pp. 1905-1911
-
-
Grossman, E.1
Messerli, F.H.2
Neutel, J.M.3
-
18
-
-
0035852724
-
Angiotensin II type 1 receptor blockers
-
BURNIER M: Angiotensin II type 1 receptor blockers. Circulation (2001) 103:904-912.
-
(2001)
Circulation
, vol.103
, pp. 904-912
-
-
Burnier, M.1
-
19
-
-
0034869208
-
Comparison of angiotensin II receptor antagonists
-
KIRCH W, HORN B, SCHWEIZER J: Comparison of angiotensin II receptor antagonists. Eur. J. Clin. Invest. (2001) 31 698-706.
-
(2001)
Eur. J. Clin. Invest.
, vol.31
, pp. 698-706
-
-
Kirch, W.1
Horn, B.2
Schweizer, J.3
-
20
-
-
0037527647
-
2003 European Society of Hypertension - European Society of Cardiology guidelines for the management of arterial hypertension
-
GUIDELINES COMMITTEE
-
GUIDELINES COMMITTEE: 2003 European Society of Hypertension - European Society of Cardiology guidelines for the management of arterial hypertension. J. Hypertens. (2003) 21:1011-1053.
-
(2003)
J. Hypertens.
, vol.21
, pp. 1011-1053
-
-
-
21
-
-
0031948041
-
Comparative pharmacology of the angiotensin II receptor antagonists
-
DZIELAK DJ: Comparative pharmacology of the angiotensin II receptor antagonists. Expert Opin. Investig. Drugs (1998) 7 741-751.
-
(1998)
Expert Opin. Investig. Drugs
, vol.7
, pp. 741-751
-
-
Dzielak, D.J.1
-
22
-
-
0030053138
-
Nonpeptide angiotensin II receptor antagonists: The next generation in antihypertensive therapy
-
WEXLER RR, GREENLEE WJ, IRVIN JD et al.: Nonpeptide angiotensin II receptor antagonists: the next generation in antihypertensive therapy. J. Med. Chem. (1996) 39:625-656.
-
(1996)
J. Med. Chem.
, vol.39
, pp. 625-656
-
-
Wexler, R.R.1
Greenlee, W.J.2
Irvin, J.D.3
-
23
-
-
0029025655
-
Recent advances: The cytochrome P450 enzymes
-
SLAUGHTER RL, EDWARDS DJ: Recent advances: the cytochrome P450 enzymes. Ann. Pharmacother. (1995) 29:619-624.
-
(1995)
Ann. Pharmacother.
, vol.29
, pp. 619-624
-
-
Slaughter, R.L.1
Edwards, D.J.2
-
24
-
-
0034119823
-
In vitro inhibition screening of human hepatic P450 enzymes by five angiotensin-II receptor antagonists
-
TAAVITSAINEN P, KIUKAANNIEMI K, PELKONEN O: In vitro inhibition screening of human hepatic P450 enzymes by five angiotensin-II receptor antagonists. Eur. J. Clin. Pharmacol. (2000) 56 135-140.
-
(2000)
Eur. J. Clin. Pharmacol.
, vol.56
, pp. 135-140
-
-
Taavitsainen, P.1
Kiukaanniemi, K.2
Pelkonen, O.3
-
25
-
-
0031957174
-
Fluconazole but not itraconazole decreases the metabolism of losartan to E-3174
-
KAUKONEN KM, OLKKOLA KT, NEUVONEN PJ: Fluconazole but not itraconazole decreases the metabolism of losartan to E-3174. Eur. J. Clin. Pharmacol. (1998) 53:445-449.
-
(1998)
Eur. J. Clin. Pharmacol.
, vol.53
, pp. 445-449
-
-
Kaukonen, K.M.1
Olkkola, K.T.2
Neuvonen, P.J.3
-
26
-
-
0030724427
-
Effect of fluconazole on the pharmacokinetics of eprosartan and losartan in healthy male volunteers
-
KAZIERAD DJ, MARTIN DE, BLUM RA et al.: Effect of fluconazole on the pharmacokinetics of eprosartan and losartan in healthy male volunteers. Clin. Pharmacol. Ther. (1997) 62:417-425.
-
(1997)
Clin. Pharmacol. Ther.
, vol.62
, pp. 417-425
-
-
Kazierad, D.J.1
Martin, D.E.2
Blum, R.A.3
-
27
-
-
0036739717
-
Evaluation of potential losartan-phenytoin drug interactions in healthy volunteers
-
FISCHER TL, PIEPER JA, GRAFF DW et al.: Evaluation of potential losartan-phenytoin drug interactions in healthy volunteers. Clin. Pharmacol. Ther. (2002) 72:238-246.
-
(2002)
Clin. Pharmacol. Ther.
, vol.72
, pp. 238-246
-
-
Fisher, T.L.1
Pieper, J.A.2
Graff, D.W.3
-
29
-
-
0029972753
-
Phenobarbital minimally alters plasma concentrations of losartan and its active metabolite E-3174
-
GOLDBERG MR, LO MW, DEUTSCH PJ, WILSON SE, MCWILLIAMS EJ, MCCREA JB: Phenobarbital minimally alters plasma concentrations of losartan and its active metabolite E-3174. Clin. Pharmacol. Ther. (1996) 59:268-274.
-
(1996)
Clin. Pharmacol. Ther.
, vol.59
, pp. 268-274
-
-
Golberg, M.R.1
Lo, M.W.2
Deutsch, P.J.3
Wilson, S.E.4
McWilliams, E.J.5
McCrea, J.B.6
-
30
-
-
0031892332
-
Effects of erythromycin or rifampin on losartan pharmacokinetics in healthy volunteers
-
WILLIAMSON KM, PATTERSON JH, MCQUEEN RH, ADAMS KF Jr, PIEPER JA: Effects of erythromycin or rifampin on losartan pharmacokinetics in healthy volunteers. Clin. Pharmacol. Ther. (1998) 63:316-323.
-
(1998)
Clin. Pharmacol. Ther.
, vol.63
, pp. 316-323
-
-
Williamson, K.M.1
Patterson, J.H.2
McQueen, R.H.3
Adams Jr., K.F.4
Pieper, J.A.5
-
31
-
-
0029954329
-
Angiotensin II receptor antagonists: The prototype losartan
-
SCHAEFER KL, PORTER JA: Angiotensin II receptor antagonists: the prototype losartan. Ann. Pharmacother. (1996) 30:625-636.
-
(1996)
Ann. Pharmacother.
, vol.30
, pp. 625-636
-
-
Schaefer, K.L.1
Porter, J.A.2
-
32
-
-
0028849020
-
Effects of cimetidine on pharmacokinetics and pharmacodynamics of losartan, an AT1-selective non-peptide angiotensin II receptor antagonist
-
GOLDBERG MR, LO MW, BRADSTREET TE, RITTER MA, HOGLUND P: Effects of cimetidine on pharmacokinetics and pharmacodynamics of losartan, an AT1-selective non-peptide angiotensin II receptor antagonist. Eur. J. Clin. Pharmacol. (1995) 49:115-119.
-
(1995)
Eur. J. Clin. Pharmacol.
, vol.49
, pp. 115-119
-
-
Goldberg, M.R.1
Lo, M.W.2
Bradstreet, T.E.3
Ritter, M.A.4
Hoglund, P.5
-
34
-
-
0035022460
-
The effect of ACE inhibitor and angiotensin II receptor antagonist therapy on serum uric acid levels and potassium homeostasis in hypertensive renal transplant recipients treated with CsA
-
SCHMIDT A, GRUBER U, BOHMIG G, KOLLER E, MAYER G: The effect of ACE inhibitor and angiotensin II receptor antagonist therapy on serum uric acid levels and potassium homeostasis in hypertensive renal transplant recipients treated with CsA. Nephrol. Dial. Transplant. (2001) 16:1034-1037.
-
(2001)
Nephrol. Dial. Transplant.
, vol.16
, pp. 1034-1037
-
-
Schmidt, A.1
Gruber, U.2
Bohmig, G.3
Koller, E.4
Mayer, G.5
-
35
-
-
0031741629
-
Efficacy and safety of losartan in the treatment of hypertension in renal transplant recipients
-
DEL CASTILLO D, CAMPISTOL JM, GUIRADO L et al.: Efficacy and safety of losartan in the treatment of hypertension in renal transplant recipients. Kidney Int. (1998) 68:S135-S139.
-
(1998)
Kidney Int.
, vol.68
-
-
Del Castillo, D.1
Campistol, J.M.2
Guirado, L.3
-
36
-
-
0034896135
-
Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers
-
ZAIDENSTEIN R, SOBACK S, GIPS M et al.: Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers. Ther. Drug Monit. (2001) 23:369-373.
-
(2001)
Ther. Drug Monit.
, vol.23
, pp. 369-373
-
-
Zaidenstein, R.1
Soback, S.2
Gips, M.3
-
37
-
-
6544294068
-
Effect of pain and nonsteroidal analgesics on blood pressure
-
CHAWLA PS, KOCHAR MS: Effect of pain and nonsteroidal analgesics on blood pressure. WMJ (1999) 98:22-29.
-
(1999)
WMJ
, vol.98
, pp. 22-29
-
-
Chawla, P.S.1
Kochar, M.S.2
-
38
-
-
0033817582
-
Effect of indomethacin on blood pressure lowering by captopril and losartan in hypertensive patients
-
CONLIN PR, MOORE TJ, SWARTZ SL et al.: Effect of indomethacin on blood pressure lowering by captopril and losartan in hypertensive patients. Hypertension (2000) 36:461-465.
-
(2000)
Hypertension
, vol.36
, pp. 461-465
-
-
Conlin, P.R.1
Moore, T.J.2
Swartz, S.L.3
-
39
-
-
0032835496
-
Effect of aspirin on blood pressure in hypertensive patients taking enalapril or losartan
-
NAWARSKAS JJ, TOWNSEND RR, CIRIGLIANO MD, SPINLER SA: Effect of aspirin on blood pressure in hypertensive patients taking enalapril or losartan. Am. J. Hypertens. (1999) 12:784-789.
-
(1999)
Am. J. Hypertens.
, vol.12
, pp. 784-789
-
-
Nawarskas, J.J.1
Townsend, R.R.2
Cirigliano, M.D.3
Spinler, S.A.4
-
40
-
-
0029593383
-
Effect of multiple doses of losartan on the pharmacokinetics of single doses of digoxin in healthy volunteers
-
DE SMET M, SCHOORS DF, DE MEYER G et al.: Effect of multiple doses of losartan on the pharmacokinetics of single doses of digoxin in healthy volunteers. Br. J. Clin. Pharmacol. (1995) 40 571-575.
-
(1995)
Br. J. Clin. Pharmacol.
, vol.40
, pp. 571-575
-
-
De Smet, M.1
Schoors, D.F.2
De Meyer, G.3
-
41
-
-
0028847447
-
Losartan does not affect the pharmacokinetics and pharmacodynamics of warfarin
-
KONG AN, TOMASKO L, WALDMAN SA et al.: Losartan does not affect the pharmacokinetics and pharmacodynamics of warfarin. J. Clin. Pharmacol. (1995) 35:1008-1015.
-
(1995)
J. Clin. Pharmacol.
, vol.35
, pp. 1008-1015
-
-
Kong, A.N.1
Tomasko, L.2
Waldman, S.A.3
-
42
-
-
0029597865
-
Absence of a pharmacokinetic interaction between losartan and hydrochlorothiazide
-
MCCREA JB, LO MW, TOMASKO L et al.: Absence of a pharmacokinetic interaction between losartan and hydrochlorothiazide. J. Clin. Pharmacol. (1995) 35:1200-1206.
-
(1995)
J. Clin. Pharmacol.
, vol.35
, pp. 1200-1206
-
-
McCrea, J.B.1
Lo, M.W.2
Tomasko, L.3
-
43
-
-
0029915382
-
Controlled trial of losartan given concomitantly with different doses of hydrochlorothiazide in hypertensive patients
-
RUILOPE LM, SIMPSON RL, TOH J, ARCURI KE, GOLDBERG AI, SWEET CS: Controlled trial of losartan given concomitantly with different doses of hydrochlorothiazide in hypertensive patients. Blood Press. (1996) 5:32-40.
-
(1996)
Blood Press.
, vol.5
, pp. 32-40
-
-
Ruilope, L.M.1
Simpson, R.L.2
Toh, J.3
Arcuri, K.E.4
Goldberg, A.I.5
Sweet, C.S.6
-
44
-
-
0033822125
-
Effect of losartan potassium, an angiotensin II receptor antagonist, on renal excretion of oxypurinol and purine bases
-
YAMAMOTO T, MORIWAKI Y, TAKAHASHI S, TSUTSUMI Z, HADA T: Effect of losartan potassium, an angiotensin II receptor antagonist, on renal excretion of oxypurinol and purine bases. J. Rheumatol. (2000) 27:2232-2236.
-
(2000)
J. Rheumatol.
, vol.27
, pp. 2232-2236
-
-
Yamamoto, T.1
Moriwaki, Y.2
Takahashi, S.3
Tsutsumi, Z.4
Hada, T.5
-
45
-
-
0029061433
-
Effects of losartan on a background of hydrochlorothiazide in patient, with hypertension
-
SOFFER BA, WRIGHT JT Jr, PRATT JH, WIENS B, GOLDBERG AI, SWEET CS: Effects of losartan on a background of hydrochlorothiazide in patient, with hypertension. Hypertension (1995) 26:112-117.
-
(1995)
Hypertension
, vol.26
, pp. 112-117
-
-
Soffer, B.A.1
Wright Jr., J.T.2
Pratt, J.H.3
Wiens, B.4
Goldberg, A.I.5
Sweet, C.S.6
-
46
-
-
1542510891
-
Uric acid: Role in cardiovascular disease and effects of losartan
-
ALDERMAN M, AIYER KJ: Uric acid: role in cardiovascular disease and effects of losartan. Curr. Med. Res. Opin. (2004) 20 369-379.
-
(2004)
Curr. Med. Res. Opin.
, vol.20
, pp. 369-379
-
-
Alderman, M.1
Aiyer, K.J.2
-
47
-
-
0032722880
-
Safety of losartan in hypertensive patients with thiazide-induced hyperuricemia
-
SHAHINFAR S, SIMPSON RL, CARIDES AD et al.: Safety of losartan in hypertensive patients with thiazide-induced hyperuricemia. Kidney Int. (1999) 56:1879-1885.
-
(1999)
Kidney Int.
, vol.56
, pp. 1879-1885
-
-
Shahinfar, S.1
Simpson, R.L.2
Carides, A.D.3
-
48
-
-
0030763446
-
Lithium intoxication in an elderly patient after combined treatment with losartan
-
BLANCHE P, RAYNAUD E, KEROB D, GALEZOWSKI N: Lithium intoxication in an elderly patient after combined treatment with losartan. Eur. J. Clin. Pharmacol. (1997) 52:501.
-
(1997)
Eur. J. Clin. Pharmacol.
, vol.52
, pp. 501
-
-
Blanche, P.1
Raynaud, E.2
Kerob, D.3
Galezoski, N.4
-
49
-
-
0030896929
-
Protein binding in plasma of valsartan, a new angiotensin II receptor antagonist
-
COLUSSI DM, PARISOT C, ROSSOLINO ML, BRUNNER LA, LEFEVRE GY: Protein binding in plasma of valsartan, a new angiotensin II receptor antagonist. J. Clin. Pharmacol. (1997) 37:214-221.
-
(1997)
J. Clin. Pharmacol.
, vol.37
, pp. 214-221
-
-
Colussi, D.M.1
Parisot, C.2
Rossolino, M.L.3
Brunner, L.A.4
Lefevre, G.Y.5
-
50
-
-
0031022244
-
Pharmacokinetics, disposition and biotransformation of [14C]-radiolabelled valsartan in healthy male volunteers after a single oral dose
-
WALDMEIER F, FLESCH G, MULLER P et al.: Pharmacokinetics, disposition and biotransformation of [14C]-radiolabelled valsartan in healthy male volunteers after a single oral dose. Xenobiotica (1997) 27:59-71.
-
(1997)
Xenobiotica
, vol.27
, pp. 59-71
-
-
Waldmeier, F.1
Flesch, G.2
Muller, P.3
-
51
-
-
0008761345
-
Comparison of enalapril and valsartan in cyclosporin A-induced hypertension and nephrotoxicity in spontaneously hypertensive rats on high-sodium diet
-
LASSILA M, FINCKENBERG P, PERE AK et al.: Comparison of enalapril. and valsartan in cyclosporin A-induced hypertension and nephrotoxicity in spontaneously hypertensive rats on high-sodium diet. Br. J. Pharmacol. (2000) 130:1339-1347.
-
(2000)
Br. J. Pharmacol.
, vol.130
, pp. 1339-1347
-
-
Lassila, M.1
Finckenberg, P.2
Pere, A.K.3
-
52
-
-
0034039783
-
Potential drug interaction between lithium and valsartan
-
LEUNG M, REMICK RA: Potential drug interaction between lithium and valsartan. J. Clin. Psychopharmacol. (2000) 20 392-393.
-
(2000)
J. Clin. Psychopharmacol.
, vol.20
, pp. 392-393
-
-
Leung, M.1
Remick, R.A.2
-
53
-
-
2342644143
-
Drug-induced lithium toxicity in the elderly: A population-based study
-
JUURLINK DN, MAMDANI MM, KOPP A, ROCHON PA, SHULMAN KI, REDELMEIER DA: Drug-induced lithium toxicity in the elderly: a population-based study. J. Am. Geriatr. Soc. (2004) 52 794-798.
-
(2004)
J. Am. Geriatr. Soc.
, vol.52
, pp. 794-798
-
-
Juurlink, D.N.1
Mamdani, M.M.2
Kopp, A.3
Rochon, P.A.4
Shulman, K.I.5
Redelmeier, D.A.6
-
54
-
-
0030859254
-
Pharmacokinetic and pharmacodynamic interaction of single oral doses of valsartan and furosemide
-
BINDSCHEDLER M, DEGEN P, FLESCH G, DE GASPARO M, PREISWERK G: Pharmacokinetic and pharmacodynamic interaction of single oral doses of valsartan and furosemide. Eur. J. Clin. Pharmacol. (1997) 52 371-378.
-
(1997)
Eur. J. Clin. Pharmacol.
, vol.52
, pp. 371-378
-
-
Bindschedler, M.1
Degen, P.2
Flesch, G.3
De Gasparo, M.4
Preiswerk, G.5
-
56
-
-
12544253051
-
-
NO AUTHORS LISTED: Diovan® (valsartan) - Sifton DW (Ed.), Montvale (NJ), Medical Economics Co., Inc
-
NO AUTHORS LISTED: Diovan® (valsartan) - In: Physicians desk reference (Volume 55). Sifton DW (Ed.), Montvale (NJ), Medical Economics Co., Inc. (2001):2166-2167.
-
(2001)
Physicians Desk Reference
, vol.55
, pp. 2166-2167
-
-
-
57
-
-
0027281668
-
Inhibition of rabbit aortic angiotensin II (AII) receptor by CV-11974, a new nonpeptide AII antagonist
-
NODA M, SHIBOUTAY, INADA Y et al.: Inhibition of rabbit aortic angiotensin II (AII) receptor by CV-11974, a new nonpeptide AII antagonist. Biochem. Pharmacol. (1993) 46:311-318.
-
(1993)
Biochem. Pharmacol.
, vol.46
, pp. 311-318
-
-
Noda, M.1
Shiboutay, A.2
Inada, Y.3
-
58
-
-
0030661709
-
Pharmacokinetic drug interaction studies with candesartan cilexetil
-
JONKMAN JH, VAN LIER JJ, VAN HEININGEN PN, LINS R, SENNEWALD R, HOGEMANN A: Pharmacokinetic drug interaction studies with candesartan cilexetil. J. Hum. Hypertens. (1997) 11:31-35.
-
(1997)
J. Hum. Hypertens.
, vol.11
, pp. 31-35
-
-
Jonkman, J.H.1
Van Lier, J.J.2
Van Heiningen, P.N.3
Lins, R.4
Sennewald, R.5
Hogemann, A.6
-
59
-
-
0020549612
-
Pharmacokinetics of hydrochlorothiazide in relation to renal function
-
NIEMEYER C, HASENFUSS G, WAIS U, KNAUF H, SCHAFER-KORTING M, MUTSCHLER E: Pharmacokinetics of hydrochlorothiazide in relation to renal function. Eur. J. Clin. Pharmacol. (1983) 24:661-665.
-
(1983)
Eur. J. Clin. Pharmacol.
, vol.24
, pp. 661-665
-
-
Niemeyer, C.1
Hasenfuss, G.2
Wais, U.3
Knauf, H.4
Schafer-Korting, M.5
Mutschler, E.6
-
60
-
-
0036271824
-
Candesartan cilexetil: An update of its use in essential hypertension
-
EASTHOPE SE, JARVIS B: Candesartan cilexetil: an update of its use in essential hypertension. Drugs (2002) 62:1253-1287.
-
(2002)
Drugs
, vol.62
, pp. 1253-1287
-
-
Easthope, S.E.1
Jarvis, B.2
-
61
-
-
0027490969
-
Pharmacological characterization of SR 47436, a new nonpeptide AT1 subtype angiotensin II receptor antagonist
-
CAZAUBON C, GOUGAT J, BOUSQUET F et al.: Pharmacological characterization of SR 47436, a new nonpeptide AT1 subtype angiotensin II receptor antagonist. J. Pharmacol. Exp. Ther. (1993) 265:826-834.
-
(1993)
J. Pharmacol. Exp. Ther.
, vol.265
, pp. 826-834
-
-
Cazaubon, C.1
Gougat, J.2
Bousquet, F.3
-
62
-
-
0028990719
-
Effects of irbesartan (SR47436/BMS-186295) on angiotensin II-induced pressor responses in the pithed rat: Potential mechanisms of action
-
CHRISTOPHE B, LIBON R, CAZAUBON C, NISATO D, MANNING A, CHATELAIN P: Effects of irbesartan (SR47436/BMS-186295) on angiotensin II-induced pressor responses in the pithed rat: potential mechanisms of action. Eur. J. Pharmacol. (1995) 281:161-171.
-
(1995)
Eur. J. Pharmacol.
, vol.281
, pp. 161-171
-
-
Christophe, B.1
Libon, R.2
Cazaubon, C.3
Nisato, D.4
Manning, A.5
Chatelain, P.6
-
63
-
-
0031418316
-
The new angiotensin II receptor antagonist, irbesartan: Pharmacokinetic and pharmacodynamic considerations
-
BRUNNER HR: The new angiotensin II receptor antagonist, irbesartan: pharmacokinetic and pharmacodynamic considerations. Am. J. Hyperterns. (1997) 10:311-317.
-
(1997)
Am. J. Hyperterns.
, vol.10
, pp. 311-317
-
-
Brunner, H.R.1
-
64
-
-
0032935655
-
Role of cytochrome P4502C9 in irbesartan oxidation by human liver microsomes
-
BOURRIE M, MEUNIER V, BERGER Y, FABRE G: Role of cytochrome P4502C9 in irbesartan oxidation by human liver microsomes. Drug Metab. Dispos. (1999) 27:288-296.
-
(1999)
Drug Metab. Dispos.
, vol.27
, pp. 288-296
-
-
Bourrie, M.1
Meunier, V.2
Berger, Y.3
Fabre, G.4
-
65
-
-
0032834554
-
Irbesartan does not affect the steady-state pharmacodynamic and pharmacokinetics of warfarin
-
MANGOLD B, GIELSDORF W. MARINO MR: Irbesartan does not affect the steady-state pharmacodynamic and pharmacokinetics of warfarin. Eur. J. Clin. Pharmacol. (1999) 55:593-598.
-
(1999)
Eur. J. Clin. Pharmacol.
, vol.55
, pp. 593-598
-
-
Mangold, B.1
Gielsdorf, W.2
Marino, M.R.3
-
67
-
-
0033672869
-
Irbesartan does not affect the pharmacokinetics of simvastatin in healthy subjects
-
MARINO MR, VACHHARAJANI NN, HADJILAMBRIS OW: Irbesartan does not affect the pharmacokinetics of simvastatin in healthy subjects. J. Clin. Pharmacol. (2000) 40:875-879.
-
(2000)
J. Clin. Pharmacol.
, vol.40
, pp. 875-879
-
-
Marino, M.R.1
Vachharajani, N.N.2
Hadjilambris, O.W.3
-
68
-
-
0035820295
-
Renal safety of combined cyclooxygenase-2 (COX-2) inhibitor and angiotensin II receptor blocker administration in mild volume depletion
-
KISTLER T, AMBUHL PM: Renal safety of combined cyclooxygenase-2 (COX-2) inhibitor and angiotensin II receptor blocker administration in mild volume depletion. Swiss Med. Wkly (2001) 131:193-198.
-
(2001)
Swiss Med. Wkly.
, vol.131
, pp. 193-198
-
-
Kistler, T.1
Ambuhl, P.M.2
-
69
-
-
0032900062
-
A review of eprosartan pharmacokinetic and pharmacodynamic drug interaction studies
-
BLUM RA, KAZIERAD DJ, TENERO DM: A review of eprosartan pharmacokinetic and pharmacodynamic drug interaction studies. Pharmacotherapy (1999) 19:79-85.
-
(1999)
Pharmacotherapy
, vol.19
, pp. 79-85
-
-
Blum, R.A.1
Kazierad, D.J.2
Tenero, D.M.3
-
70
-
-
0035215475
-
Eprosartan versus enalapril in elderly patients with hypertension: A double-blind, randomized trial
-
RUILOPE L, JAGER B, PRICHARD B: Eprosartan versus enalapril in elderly patients with hypertension: a double-blind, randomized trial. Blood Press. (2001) 10:223-229.
-
(2001)
Blood Press.
, vol.10
, pp. 223-229
-
-
Ruilope, L.1
Jager, B.2
Prichard, B.3
-
71
-
-
0031947633
-
Drug interactions at the renal level. Implications for drug development
-
BONATE PL, REITH K, WEIR S: Drug interactions at the renal level. Implications for drug development. Clin. Pharmacokinet. (1998) 34:375-404.
-
(1998)
Clin. Pharmacokinet.
, vol.34
, pp. 375-404
-
-
Bonate, P.L.1
Reith, K.2
Weir, S.3
-
72
-
-
0030874256
-
Lack of effect of eprosartan on the single dose pharmacokinetics of orally administered digoxin healthy male volunteers
-
MARTIN DE, TOMPSON D, BOIKE SC et al.: Lack of effect of eprosartan on the single dose pharmacokinetics of orally administered digoxin healthy male volunteers. Br. J. Clin. Pharmacol. (1997) 43:661-664.
-
(1997)
Br. J. Clin. Pharmacol.
, vol.43
, pp. 661-664
-
-
Martin, D.E.1
Tompson, D.2
Boike, S.C.3
-
73
-
-
0031903838
-
Eprosartan does not affect the pharmacodynamic of warfarin
-
KAZIERAD DJ, MARTIN DE, ILSON B et al.: Eprosartan does not affect the pharmacodynamic of warfarin. J. Clin. Pharmacol. (1998) 38:649-653.
-
(1998)
J. Clin. Pharmacol.
, vol.38
, pp. 649-653
-
-
Kazierad, D.J.1
Martin, D.E.2
Ilson, B.3
-
74
-
-
0030939617
-
Eprosartan, an angiotensin II receptor antagonist, does not affect the pharmacodynamics of glyburide in patient, with Type II diabetes mellitus
-
MARTIN DE, DECHERNEY GS, ILSON BE et al.: Eprosartan, an angiotensin II receptor antagonist, does not affect the pharmacodynamics of glyburide in patient, with Type II diabetes mellitus. J. Clin. Pharmacol. (1997) 37:155-159.
-
(1997)
J. Clin. Pharmacol.
, vol.37
, pp. 155-159
-
-
Martin, D.E.1
Decherney, G.S.2
Ilson, B.E.3
-
75
-
-
0031934526
-
Effect of ranitidine on the pharmacokinetics of orally administered eprosartan, an angiotensin II antagonist, in healthy male volunteers
-
TENERO DM, MARTIN DE, ILSON BE et al.: Effect of ranitidine on the pharmacokinetics of orally administered eprosartan, an angiotensin II antagonist, in healthy male volunteers. Ann. Pharmacother. (1998) 32:304-308.
-
(1998)
Ann. Pharmacother.
, vol.32
, pp. 304-308
-
-
Tenero, D.M.1
Martin, D.E.2
Ilson, B.E.3
-
76
-
-
0030724427
-
Effect of fluconazole on the pharmacokinetics of eprosartan and losartan in healthy male volunteers
-
KAZIERAD DJ, MARTIN DE, BLUM RA et al.: Effect of fluconazole on the pharmacokinetics of eprosartan and losartan in healthy male volunteers. Clin. Pharmacol. Ther. (1997) 62:417-425.
-
(1997)
Clin. Pharmacol. Ther.
, vol.62
, pp. 417-425
-
-
Kazierad, D.J.1
Martin, D.E.2
Blum, R.A.3
-
77
-
-
0036720461
-
In vitro and in vivo characterization of the activity of telmisartan: An insurmountable angiotensin II receptor antagonist
-
MAILLARD MP, PERREGAUX C, CENTENO C et al.: In vitro and in vivo characterization of the activity of telmisartan: an insurmountable angiotensin II receptor antagonist. J. Pharmacol. Exp. Ther. (2002) 302:1089-1095.
-
(2002)
J. Pharmacol. Exp. Ther.
, vol.302
, pp. 1089-1095
-
-
Maillard, M.P.1
Perregaux, C.2
Centeno, C.3
-
78
-
-
0033731288
-
Pharmacokinetics of repeated oral doses of amlodipine and amlodipine plus telmisartan in healthy volunteers
-
STANGIER J, SU CA: Pharmacokinetics of repeated oral doses of amlodipine and amlodipine plus telmisartan in healthy volunteers. J. Clin. Pharmacol. (2000) 40:1347-1354.
-
(2000)
J. Clin. Pharmacol.
, vol.40
, pp. 1347-1354
-
-
Stangier, J.1
Su, C.A.2
-
79
-
-
0034874986
-
Telmisartan: A review of its use in hypertension
-
SHARPE M, JARVIS B, GOA KL: Telmisartan: a review of its use in hypertension. Drugs (2001) 61:1501-1529.
-
(2001)
Drugs
, vol.61
, pp. 1501-1529
-
-
Sharpe, M.1
Jarvis, B.2
Goa, K.L.3
-
80
-
-
0033749283
-
Pharmacokinetics of acetaminophen and ibuprofen when co-administered with telmisartan in healthy volunteers
-
STANGIER J, SU CA, FRAUNHOFER A, TETZLOFF W: Pharmacokinetics of acetaminophen and ibuprofen when co-administered with telmisartan in healthy volunteers. J. Clin. Pharmacol. (2000) 40:1338-1346.
-
(2000)
J. Clin. Pharmacol.
, vol.40
, pp. 1338-1346
-
-
Stangier, J.1
Su, C.A.2
Fraunhofer, A.3
Tetzloff, W.4
-
81
-
-
0033732238
-
Steady-state pharmacodynamics, and pharmacokinetics of warfarin in the presence and absence of telmisartan in healthy male volunteers
-
STANGIER J, SU CA, HENDRIKS MG et al.: Steady-state pharmacodynamics, and pharmacokinetics of warfarin in the presence and absence of telmisartan in healthy male volunteers. J. Clin. Pharmacol. (2000) 40:1331-1337.
-
(2000)
J. Clin. Pharmacol.
, vol.40
, pp. 1331-1337
-
-
Stangier, J.1
Su, C.A.2
Hendriks, M.G.3
-
82
-
-
0033748479
-
The effect of telmisartan on the steady-state pharmacokinetics of digoxin in healthy male volunteers
-
STANGIER J, SU CA, HENDRIKS MG et al.: The effect of telmisartan on the steady-state pharmacokinetics of digoxin in healthy male volunteers. J. Clin. Pharmacol. (2000) 40:1373-1379.
-
(2000)
J. Clin. Pharmacol.
, vol.40
, pp. 1373-1379
-
-
Stangier, J.1
Su, C.A.2
Hendriks, M.G.3
-
83
-
-
0035131633
-
Effects of the replacement of the angiotensin-converting enzyme inhibitor enalapril by the angiotensin II receptor blocker telmisartan in patients with congestive heart failure. The replacement of angiotensin-converting enzyme inhibition (REPLACE) investigators
-
DUNSELMAN PH: Effects of the replacement of the angiotensin-converting enzyme inhibitor enalapril by the angiotensin II receptor blocker telmisartan in patients with congestive heart failure. The replacement of angiotensin-converting enzyme inhibition (REPLACE) investigators. Int. J. Cardiol. (2001) 77:131-138.
-
(2001)
Int. J. Cardiol.
, vol.77
, pp. 131-138
-
-
Dunselman, P.H.1
-
84
-
-
0028792103
-
Pharmacology of CS-866, a novel nonpeptide angiotensin II receptor antagonist
-
MIZUNO M, SADA T, IKEDA M et al.: Pharmacology of CS-866, a novel nonpeptide angiotensin II receptor antagonist. Eur. J. Pharmacol. (1995) 285:181-188.
-
(1995)
Eur. J. Pharmacol.
, vol.285
, pp. 181-188
-
-
Mizuno, M.1
Sada, T.2
Ikeda, M.3
-
85
-
-
0034951293
-
In vitro and in vivo pharmacology of olmesartan medoxomil, an angiorensin II type AT1 receptor antagonist
-
KOIKE H, SADA T, MIZUNO M: In vitro and in vivo pharmacology of olmesartan medoxomil, an angiorensin II type AT1 receptor antagonist. J. Hypertens. Suppl. (2001) 19:3-14.
-
(2001)
J. Hypertens. Suppl.
, vol.19
, pp. 3-14
-
-
Koike, H.1
Sada, T.2
Mizuno, M.3
-
86
-
-
0036071006
-
Olmesartan medoxomil
-
WARNER GT, JARVIS B: Olmesartan medoxomil. Drugs (2002) 62:1345-1353.
-
(2002)
Drugs
, vol.62
, pp. 1345-1353
-
-
Warner, G.T.1
Jarvis, B.2
-
87
-
-
0034956326
-
The pharmacokinetic and metabolic profile of olmesartan medoxomil limits the risk of clinically relevant drug interaction
-
LAEIS P, PUCHLER K, KIRCH W: The pharmacokinetic and metabolic profile of olmesartan medoxomil limits the risk of clinically relevant drug interaction. J. Hypertens. (2001) 19:21-32.
-
(2001)
J. Hypertens.
, vol.19
, pp. 21-32
-
-
Laeis, P.1
Puchler, K.2
Kirch, W.3
-
88
-
-
0038455748
-
Interaction of spironolactone with ACE inhibitors or ARBs: Analysis of 44 cases
-
WRENGER E, MULLER R, MOESENTHIN M, WELTE T, FROLICH JC, NEUMANN KH: Interaction of spironolactone with ACE inhibitors or ARBs: analysis of 44 cases. Br. Med. J. (2003) 327:147-149.
-
(2003)
Br. Med. J.
, vol.327
, pp. 147-149
-
-
Wrenger, E.1
Muller, R.2
Moesenthin, M.3
Welte, T.4
Frolich, J.C.5
Neumann, K.H.6
-
89
-
-
0023261485
-
Captopril and hydrochlorothiazide: Rationale for their combination
-
AMBROSIONI E, BORGHI C, COSTA FV: Captopril and hydrochlorothiazide: rationale for their combination. Br. J. Clin. Pharmacol. (1987) 23:43-50.
-
(1987)
Br. J. Clin. Pharmacol.
, vol.23
, pp. 43-50
-
-
Ambrosioni, E.1
Borghi, C.2
Costa, F.V.3
-
90
-
-
0020404274
-
Different interactions of indomethacin and sulindac with thiazides in hypertension
-
STEINESS E, WALDORFF S: Different interactions of indomethacin and sulindac with thiazides in hypertension. Br. Med. J. (1982) 285:1702-1703.
-
(1982)
Br. Med. J.
, vol.285
, pp. 1702-1703
-
-
Steiness, E.1
Waldorff, S.2
-
91
-
-
0027285939
-
Pharmacokinetic drug interactions with ACE inhibitors
-
SHIONOIRI H: Pharmacokinetic drug interactions with ACE inhibitors. Clin. Pharmacokinet. (1993) 25:20-58.
-
(1993)
Clin. Pharmacokinet.
, vol.25
, pp. 20-58
-
-
Shionoiri, H.1
-
92
-
-
0030062506
-
Lithium and angiotensin-converting enzyme inhibitors: Evaluation of a potential interaction
-
FINLEY PR, O'BRIEN JG, COLEMAN RW: Lithium and angiotensin-converting enzyme inhibitors: evaluation of a potential interaction. J. Clin. Pyschopharmacol. (1996) 16:68-71.
-
(1996)
J. Clin. Pyschopharmacol.
, vol.16
, pp. 68-71
-
-
Finley, P.R.1
O'brien, J.G.2
Coleman, R.W.3
-
93
-
-
2342557311
-
Design, synthesis, structural studies, biological evaluation, and computational simulations of novel potent AT(1) angiotensin II receptor antagonists based on the 4-phenylquinoline structure
-
CAPPELLI A, PERICOT MOHR GL G, GALLELLI A et al.: Design, synthesis, structural studies, biological evaluation, and computational simulations of novel potent AT(1) angiotensin II receptor antagonists based on the 4-phenylquinoline structure. J. Med. Chem. (2004) 47:2574-2586.
-
(2004)
J. Med. Chem.
, vol.47
, pp. 2574-2586
-
-
Cappelli, A.1
Pericot Mohr, G.L.G.2
Gallelli, A.3
-
94
-
-
1942452358
-
Role of angiotensin II Type 2 receptors and kinins in the cardioprotective effect of angiotensin II Type 1 receptor antagonists in rats with heart failure
-
LIU YH, YANG XP, SHESELY EG, SANKEY SS, CARRETERO OA: Role of angiotensin II Type 2 receptors and kinins in the cardioprotective effect of angiotensin II Type 1 receptor antagonists in rats with heart failure. J. Am. Coll. Cardiol. (2004) 43:1473-1480.
-
(2004)
J. Am. Coll. Cardiol.
, vol.43
, pp. 1473-1480
-
-
Liu, Y.H.1
Yang, X.P.2
Shesely, E.G.3
Sankey, S.S.4
Carretero, O.A.5
|